NovoCure Ltd (NovoCure) is an oncology company with a focus on the development and commercialization of novel delivery systems for the treatment of brain, thoracic and abdomen cancers. Its proprietary Tumor Treating Fields (TTF) technology platform uses electric fields tuned to specific frequencies to disrupt the division of solid tumor cancer cells. The company markets TTF-based delivery systems, Optune Lua for the treatment of malignant pleural mesothelioma; and Optune Gio for the treatment of glioblastoma. The products are indicated in combination with standard chemotherapies. The company has operations in five regions, namely, United States, Germany, Japan, Greater China, and Other international markets. NovoCure is headquartered in Saint Helier, Jersey, the UK.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company NovoCure Ltd
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- NovoCure Ltd Company Overview
- NovoCure Ltd Company Snapshot
- NovoCure Ltd Pipeline Products and Ongoing Clinical Trials Overview
- NovoCure Ltd - Pipeline Analysis Overview
- Business Description
- NovoCure Ltd - Key Facts
- NovoCure Ltd - Major Products and Services
- NovoCure Ltd Pipeline Products by Development Stage
- NovoCure Ltd Ongoing Clinical Trials by Trial Status
- NovoCure Ltd Pipeline Products Overview
- Maxpoint Treatment Planning Software
- Maxpoint Treatment Planning Software Product Overview
- Next Gen Field Generator
- Next Gen Field Generator Product Overview
- NovoTTF-100M System
- NovoTTF-100M System Product Overview
- NovoTTF-100M System Clinical Trial
- NovoTTF-200A - Small Cell Lung Cancer
- NovoTTF-200A - Small Cell Lung Cancer Product Overview
- NovoTTF-200T - Advanced Non-Small Cell Lung Cancer
- NovoTTF-200T - Advanced Non-Small Cell Lung Cancer Product Overview
- NovoTTF-200T - Advanced Non-Small Cell Lung Cancer Clinical Trial
- NovoTTF-200T - Pancreatic Cancer
- NovoTTF-200T - Pancreatic Cancer Product Overview
- NovoTTF-200T - Pancreatic Cancer Clinical Trial
- Optune - Brain Metastasis
- Optune - Brain Metastasis Product Overview
- Optune - Brain Metastasis Clinical Trial
- Optune - Breast Cancer
- Optune - Breast Cancer Product Overview
- Optune - Cervical Cancer
- Optune - Cervical Cancer Product Overview
- Optune - Colorectal Carcinoma
- Optune - Colorectal Carcinoma Product Overview
- Optune - Ependymoma
- Optune - Ependymoma Product Overview
- Optune - Gastric Adenocarcinoma
- Optune - Gastric Adenocarcinoma Product Overview
- Optune - Gastric Adenocarcinoma Clinical Trial
- Optune - Gliosarcoma
- Optune - Gliosarcoma Product Overview
- Optune - Liver Cancer
- Optune - Liver Cancer Product Overview
- Optune - Malignant Melanoma
- Optune - Malignant Melanoma Product Overview
- Optune - Medulloblastoma
- Optune - Medulloblastoma Product Overview
- Optune - Meningioma
- Optune - Meningioma Product Overview
- Optune - Mesothelioma
- Optune - Mesothelioma Product Overview
- Optune - Mesothelioma Clinical Trial
- Optune - Non-Small Cell Lung Cancer
- Optune - Non-Small Cell Lung Cancer Product Overview
- Optune - Non-Small Cell Lung Cancer Clinical Trial
- Optune - Ovarian Cancer
- Optune - Ovarian Cancer Product Overview
- Optune - Pancreatic Cancer
- Optune - Pancreatic Cancer Product Overview
- Optune - Pancreatic Cancer Clinical Trial
- Optune - Pediatric Glioma
- Optune - Pediatric Glioma Product Overview
- Optune - Pediatric Glioma Clinical Trial
- Optune - Renal Adenocarcinoma
- Optune - Renal Adenocarcinoma Product Overview
- Optune - Small Cell Lung Cancer
- Optune - Small Cell Lung Cancer Product Overview
- Optune - Torso Array
- Optune - Torso Array Product Overview
- Optune - Torso Array Clinical Trial
- Optune - Urinary Transitional Cell Carcinoma
- Optune - Urinary Transitional Cell Carcinoma Product Overview
- Optune Plus Bevacizumab - Recurrent Glioblastoma
- Optune Plus Bevacizumab - Recurrent Glioblastoma Product Overview
- Optune Plus Bevacizumab - Recurrent Glioblastoma Clinical Trial
- Optune With Marizomib And Temozolomide - Glioblastoma
- Optune With Marizomib And Temozolomide - Glioblastoma Product Overview
- Optune With Pembrolizumab And Temozolomide
- Optune With Pembrolizumab And Temozolomide Product Overview
- Optune With Pembrolizumab And Temozolomide Clinical Trial
- NovoCure Ltd - Key Competitors
- NovoCure Ltd - Key Employees
- NovoCure Ltd - Key Employee Biographies
- NovoCure Ltd - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- NovoCure Ltd, Recent Developments
- Aug 17, 2024: NovoCure Receives Additional FDA 510(k) Clearance for Optune Lua (NovoTTF-100L System)
- Aug 14, 2024: Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer
- Jul 25, 2024: Novocure Reports Second Quarter 2024 Financial Results
- Jun 03, 2024: METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
- May 23, 2024: TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
- Apr 24, 2024: Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
- Apr 05, 2024: Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research Annual Meeting 2024
- Mar 27, 2024: Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
- Jan 18, 2024: Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
- Jan 09, 2024: Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- NovoCure Ltd Pipeline Products and Ongoing Clinical Trials Overview
- NovoCure Ltd Pipeline Products by Equipment Type
- NovoCure Ltd Pipeline Products by Indication
- NovoCure Ltd Ongoing Clinical Trials by Trial Status
- NovoCure Ltd, Key Facts
- NovoCure Ltd, Major Products and Services
- NovoCure Ltd Number of Pipeline Products by Development Stage
- NovoCure Ltd Pipeline Products Summary by Development Stage
- NovoCure Ltd Ongoing Clinical Trials by Trial Status
- NovoCure Ltd Ongoing Clinical Trials Summary
- Maxpoint Treatment Planning Software - Product Status
- Maxpoint Treatment Planning Software - Product Description
- Next Gen Field Generator - Product Status
- Next Gen Field Generator - Product Description
- NovoTTF-100M System - Product Status
- NovoTTF-100M System - Product Description
- NovoTTF-100M System - Pivotal, Open-label, Randomized Study of Radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC)
- NovoTTF-100M System - Safety and Efficacy of SRS and Immune Checkpoint Inhibitors (ICI) Concurrent With NovoTTF-100M in Melanoma Brain Metastases
- NovoTTF-200A - Small Cell Lung Cancer - Product Status
- NovoTTF-200A - Small Cell Lung Cancer - Product Description
- NovoTTF-200T - Advanced Non-Small Cell Lung Cancer - Product Status
- NovoTTF-200T - Advanced Non-Small Cell Lung Cancer - Product Description
- NovoTTF-200T - Advanced Non-Small Cell Lung Cancer - A Feasibility Study to Evaluate the Addition of Tumor Treating Fields to Treatment of Locally Advanced Stage III NSCLC
- NovoTTF-200T - Advanced Non-Small Cell Lung Cancer - LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
- NovoTTF-200T - Advanced Non-Small Cell Lung Cancer - LUNAR-4: Pilot, Single Arm, Open-Label, Multinational Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) Previously Treated With a PD-1/PD-L1 Inhibitor and Platinum-Based Chemotherapy
- NovoTTF-200T - Advanced Non-Small Cell Lung Cancer - Phase 0 Trial of Pre-operative Tumor Treating Fields in Patients with Resectable Lung Cancer
- NovoTTF-200T - Pancreatic Cancer - Product Status
- NovoTTF-200T - Pancreatic Cancer - Product Description
- NovoTTF-200T - Pancreatic Cancer - A Phase II Study of Peri-Operative NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
- Optune - Brain Metastasis - Product Status
- Optune - Brain Metastasis - Product Description
- Optune - Brain Metastasis - Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
- Optune - Breast Cancer - Product Status
- Optune - Breast Cancer - Product Description
- Optune - Cervical Cancer - Product Status
- Optune - Cervical Cancer - Product Description
- Optune - Colorectal Carcinoma - Product Status
- Optune - Colorectal Carcinoma - Product Description
- Optune - Ependymoma - Product Status
- Optune - Ependymoma - Product Description
- Optune - Gastric Adenocarcinoma - Product Status
- Optune - Gastric Adenocarcinoma - Product Description
- Optune - Gastric Adenocarcinoma - A Phase II Pilot Study of Tumor Treating Fields Together with Chemotherapy as First-line Treatment of Gastric Cancer
- Optune - Gliosarcoma - Product Status
- Optune - Gliosarcoma - Product Description
- Optune - Liver Cancer - Product Status
- Optune - Liver Cancer - Product Description
- Optune - Malignant Melanoma - Product Status
- Optune - Malignant Melanoma - Product Description
- Optune - Medulloblastoma - Product Status
- Optune - Medulloblastoma - Product Description
- Optune - Meningioma - Product Status
- Optune - Meningioma - Product Description
- Optune - Mesothelioma - Product Status
- Optune - Mesothelioma - Product Description
- Optune - Mesothelioma - TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study - TIGER Meso Study
- Optune - Non-Small Cell Lung Cancer - Product Status
- Optune - Non-Small Cell Lung Cancer - Product Description
- Optune - Non-Small Cell Lung Cancer - EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
- Optune - Ovarian Cancer - Product Status
- Optune - Ovarian Cancer - Product Description
- Optune - Pancreatic Cancer - Product Status
- Optune - Pancreatic Cancer - Product Description
- Optune - Pancreatic Cancer - Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
- Optune - Pediatric Glioma - Product Status
- Optune - Pediatric Glioma - Product Description
- Optune - Pediatric Glioma - Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma or Ependymoma, and Feasibility and Efficacy Trial of Optune in Conjunction With Radiation Therapy for Children With Newly Diagnosed DIPG
- Optune - Pediatric Glioma - HUMC 1612: A Phase I Trial of the Optune NovoTTF-200A System With Concomitant Temozolomide and Bevacizumab in Pediatric Patients With High-grade Glioma
- Optune - Renal Adenocarcinoma - Product Status
- Optune - Renal Adenocarcinoma - Product Description
- Optune - Small Cell Lung Cancer - Product Status
- Optune - Small Cell Lung Cancer - Product Description
- Optune - Torso Array - Product Status
- Optune - Torso Array - Product Description
- Optune - Torso Array - A Clinical Usability Study of Torso Array to Improve Patient Comfort for All Torso and Abdominal Indications
- Optune - Urinary Transitional Cell Carcinoma - Product Status
- Optune - Urinary Transitional Cell Carcinoma - Product Description
- Optune Plus Bevacizumab - Recurrent Glioblastoma - Product Status
- Optune Plus Bevacizumab - Recurrent Glioblastoma - Product Description
- Optune Plus Bevacizumab - Recurrent Glioblastoma - A Phase II Trial of Tumor Treating Fields (TTfields) Concomitant with Radiosurgery for the Treatment of Recurrent, Bevacizumab-naïve Glioblastoma
- Optune With Marizomib And Temozolomide - Glioblastoma - Product Status
- Optune With Marizomib And Temozolomide - Glioblastoma - Product Description
- Optune With Pembrolizumab And Temozolomide - Product Status
- Optune With Pembrolizumab And Temozolomide - Product Description
- Optune With Pembrolizumab And Temozolomide - Phase II, Single Arm, Historically Controlled Study Testing the Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune) Plus Pembrolizumab in Patients with Newly Diagnosed Glioblastoma (2-THE-TOP)
- NovoCure Ltd, Key Employees
- NovoCure Ltd, Key Employee Biographies
- NovoCure Ltd, Subsidiaries
- Glossary
- NovoCure Ltd Pipeline Products by Equipment Type
- NovoCure Ltd Pipeline Products by Development Stage
- NovoCure Ltd Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Advanz Pharma Corp Ltd
- SonALASense Inc
- MDxHealth SA
- Monteris Medical Inc
- MagForce AG
